Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Stock Down 1.4 %

Shares of NASDAQ:TENX opened at $3.57 on Wednesday. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $61.20. The stock’s 50-day moving average price is $3.72 and its 200-day moving average price is $3.63.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. On average, equities research analysts predict that Tenax Therapeutics will post -6.68 earnings per share for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.